pirenzepine has been researched along with Cushing Syndrome in 1 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Cushing Syndrome: A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shimizu, C | 1 |
| Yamane, Y | 1 |
| Ishizuka, T | 1 |
| Kijima, H | 1 |
| Takano, K | 1 |
| Takano, A | 1 |
| Kubo, M | 1 |
| Koike, T | 1 |
1 other study available for pirenzepine and Cushing Syndrome
| Article | Year |
|---|---|
Involvement of the cholinergic pathway in the pathogenesis of pituitary Cushing's syndrome.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adenoma; Adrenocorticotropic Hormone; Atropine; Choline; | 2001 |